Your session is about to expire
What is Venclexta
VenetoclaxThe Generic name of this drug
Treatment SummaryVenetoclax is a medication used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma. The drug works by blocking the BCL-2 proteins that prevent cells from dying naturally. It was first approved by the FDA in 2016 and was recently approved for use in patients who have had prior treatments. Venetoclax is more powerful than its predecessor, navitoclax, and is used to induce apoptosis (programmed cell death) in CLL cells.
Venclextais the brand name
Venclexta Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Venclexta
Venetoclax
2016
4
Approved as Treatment by the FDA
Venetoclax, otherwise known as Venclexta, is approved by the FDA for 3 uses such as Acute Myeloid Leukemia and Newly Diagnosed .Acute Myeloid Leukemia
Used to treat Acute Myeloid Leukemia (AML) in combination with Cytarabine
Newly Diagnosed
Used to treat Newly Diagnosed in combination with Cytarabine
Comorbidities
Used to treat Comorbidities in combination with Cytarabine
Effectiveness
How Venclexta Affects PatientsVenetoclax is a drug used to treat chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) that works by causing the death of cancer cells. It has been found to be safe and effective in producing positive responses in patients with CLL or SLL, even those with a poor prognosis. It is not expected to have any major effects on the heart. Studies have shown that venetoclax has a success rate of around 80% in treating various types of blood cancers.
How Venclexta works in the bodyVenetoclax works to restore the process of cell death (apoptosis) in cancerous cells. It does this by directly attaching to BCL-2 proteins, which helps to replace the proteins that are responsible for keeping the cancer alive. This leads to the cancer cells being broken down and destroyed by enzymes, without causing too much damage to healthy cells. Venetoclax has been proven to be effective in treating some types of cancer, as well as reducing the side effects of other cancer treatments.
When to interrupt dosage
The measure of Venclexta is reliant upon the identified sickness. The amount of dosage fluctuates as per the strategy of delivery (e.g. Oral or Tablet) featured in the table beneath.Condition
Dosage
Administration
Comorbidities
10.0 mg, , 50.0 mg, 100.0 mg, 260.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit; Tablet, Kit; Tablet - Oral
Small Lymphocytic Lymphoma
10.0 mg, , 50.0 mg, 100.0 mg, 260.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit; Tablet, Kit; Tablet - Oral
Chronic Lymphocytic Leukemia
10.0 mg, , 50.0 mg, 100.0 mg, 260.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit; Tablet, Kit; Tablet - Oral
Acute Myeloid Leukemia
10.0 mg, , 50.0 mg, 100.0 mg, 260.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit; Tablet, Kit; Tablet - Oral
Newly Diagnosed
10.0 mg, , 50.0 mg, 100.0 mg, 260.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit; Tablet, Kit; Tablet - Oral
Warnings
Venclexta ContraindicationsCondition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Common Venclexta Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Venetoclax.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Venetoclax.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Venetoclax.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Venetoclax.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Venetoclax.
Venclexta Toxicity & Overdose RiskVenetoclax has been found to have an oral toxicity in mice of over 2001mg/kg. Taking Venetoclax while pregnant can be harmful to the baby. Men taking this drug may experience decreased fertility. There have not been any studies done yet to assess if Venetoclax can cause cancer. Tests for mutagenicity, chromosomal aberrations, and clastogenicity have all been negative.
Venclexta Novel Uses: Which Conditions Have a Clinical Trial Featuring Venclexta?
243 active studies are presently examining the potential of Venclexta in providing therapeutic benefits for Small Lymphocytic Lymphoma.Condition
Clinical Trials
Trial Phases
Comorbidities
2 Actively Recruiting
Not Applicable, Phase 2
Newly Diagnosed
3 Actively Recruiting
Phase 3, Phase 1
Small Lymphocytic Lymphoma
13 Actively Recruiting
Phase 2, Phase 1, Phase 3
Acute Myeloid Leukemia
274 Actively Recruiting
Phase 2, Phase 1, Phase 3, Phase 4, Not Applicable, Early Phase 1
Chronic Lymphocytic Leukemia
149 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4
Venclexta Reviews: What are patients saying about Venclexta?
5Patient Review
5/10/2018 I can only tolerate 50 mg of this drug, but it is very effective. Higher doses give me flu like symptoms.
5Patient Review
9/27/2017